MYGN vs NTLA
Myriad Genetics Inc. and Intellia Therapeutics, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | MYGN | NTLA |
|---|---|---|
| Revenue | $824.5M | $67.7M |
| Net income | $-365.9M | $-412.7M |
| Gross margin | 69.9% | · |
| Net margin | −44.4% | −609.9% |
| Return on equity | −68.5% | −53.5% |
| Diluted EPS | −$3.95 | −$3.81 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | $-395.9M |
| Equity | $368.0M | $671.4M |
| Net debt / equity | −0.08× | · |
| Current ratio | 2.49× | 5.08× |
| Revenue CAGR 5y | 8.2% | 3.1% |
| Profit CAGR 5y | · | · |
MYGN bills 12.2× the revenue of NTLA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | MYGN | NTLA |
|---|---|---|
| FY2025 | $824.5M | $67.7M |
| FY2024 | $837.6M | $57.9M |
| FY2023 | $753.2M | $36.3M |
| FY2022 | $678.4M | $52.1M |
| FY2021 | $690.6M | $33.1M |
| FY2020 | $557.1M | $58.0M |
| FY2019 | $638.6M | $43.1M |
| FY2018 | $851.1M | $30.4M |
| FY2017 | $743.7M | $26.1M |
| FY2016 | $728.7M | $16.5M |
Bottom line
| Fiscal year | MYGN | NTLA |
|---|---|---|
| FY2025 | $-365.9M | $-412.7M |
| FY2024 | $-127.3M | $-519.0M |
| FY2023 | $-263.3M | $-481.2M |
| FY2022 | $-112.0M | $-474.2M |
| FY2021 | $-27.2M | $-267.9M |
| FY2020 | $-223.6M | $-134.2M |
| FY2019 | $-199.5M | $-474.2M |
| FY2018 | $4.6M | $-85.3M |
| FY2017 | $133.3M | $-67.5M |
| FY2016 | $17.4M | $-31.6M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$756,829,000 | MYGN |
| FY2024 | +$779,723,000 | MYGN |
| FY2023 | +$716,925,000 | MYGN |
| FY2022 | +$626,279,000 | MYGN |
| FY2021 | +$657,547,000 | MYGN |
| FY2020 | +$499,106,000 | MYGN |
| FY2019 | +$595,497,000 | MYGN |
| FY2018 | +$820,666,000 | MYGN |
| FY2017 | +$717,583,000 | MYGN |
| FY2016 | +$712,221,000 | MYGN |
MYGN has reported the higher revenue in every one of these 10 fiscal years. The gap has widened since the earliest year compared.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +565.5 pp | MYGN |
| FY2024 | +881.6 pp | MYGN |
| FY2023 | +1291.6 pp | MYGN |
| FY2022 | +893.3 pp | MYGN |
| FY2021 | +806.6 pp | MYGN |
| FY2020 | +191.3 pp | MYGN |
| FY2019 | +199.7 pp | MYGN |
| FY2018 | +280.9 pp | MYGN |
| FY2017 | +276.5 pp | MYGN |
| FY2016 | +194.3 pp | MYGN |
MYGN has kept the higher net margin in every one of these 10 fiscal years.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's net margin has been more volatile than MYGN's over the 10 comparable fiscal years — 375.1 percentage points of standard deviation against 19.7.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
MYGN led in net margin in every one of the 10 comparable fiscal years — a structural lead, not a recent swing.
10 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NTLA's return on equity has been more volatile than MYGN's over the 9 comparable fiscal years — 43.0 percentage points of standard deviation against 22.3.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between MYGN and NTLA over these 9 fiscal years — MYGN led in 8 and NTLA in 1.
9 of 18 comparable fiscal years — a year missing data on either side is not counted.